Aurora Cannabis has launched three new cannabis extracts for patients in the United Kingdom. Available starting in May, and produced at Aurora Nordic in Odense, Denmark, the extracts have a particularly rich terpene profile. Terpenes in combination with cannabinoids are an important contributor to the therapeutic effect of cannabis.
At Aurora Nordic, a new extraction process has been developed to ensure the terpene profile of its products consistently remains at a high level. The extraction process is based on identical flower varieties and results in reliable concentrations of active ingredients and consistent terpene profiles, and ensures the safety and tolerability of the treatment. Aurora’s new extracts will expand the range of possible treatment options for patients in the UK.
Aurora entered the UK medical cannabis market in 2019, just a few months following legalization. Although thousands of patients benefit from medical cannabis today, widespread accessibility is still a long way off and many obstacles remain.
“We continue to strive for accessibility for all patients that have been prescribed medical cannabis and advocate for reimbursement and affordability through NHS funding. We are dedicated to helping improve access to medical education for healthcare professionals
and are happy to share our medicinal cannabis knowledge and expertise,” stated Trisha Cassidy, Managing Director, Aurora UK & Ireland. “The effectiveness and tolerability of medical cannabis has already been shown in several clinical studies and even more data
from 20,000 UK patients will become available once the first patient registry for medical cannabis in Europe is completed.The UK market is still young and much work needs to be done to dismantle the obstacles that continue to prevent patients from receiving the
treatment they need. Aurora is committed to these patients and will continue its dedicated work in the UK.”
Aurora, a passionate advocate for patient access to medical cannabis and the market leader in premium dried flower for the UK and Europe, produces the majority of their medical cannabis products for the European market in a state-of-the-art manufacturing facility at Aurora Nordic in Odense, Denmark. Aurora adheres to the strictest regulations for EU-GMP (Good Manufacturing Practice) and appreciates its locational advantage for a secure supply for patients in the UK.
For more information:Aurora
www.auroramj.com


Announcements
Job Offers
Top 5 -yesterday
- Does DLC certification really matter when you’re choosing a lighting system?
- “We need more data to understand the environmental impact of cannabis cultivation”
- DK: "Impressive test results show extreme product purity without radiation"
- Contaminated cannabis in Arizona: Your questions answered
- New highlights Greentech Amsterdam
Top 5 -last week
- Aurora to shut down Aurora Sky facility
- “$13 million government grant shows trust in the NZ organic medicinal cannabis industry”
- US (OK): Tornado hits medical cannabis farm, nearly all 50 greenhouses destroyed
- “Third-party testing would prevent growers’ disappointment with the quality of their lights”
- Cultivating medical cannabis in South Africa: "High standards and costly, but profitable"
Top 5 -last month
- Aurora to shut down Aurora Sky facility
- Takeaways from the Legal Cannabis Coalition's symposium
- Canadian grower shows how to grow premium cannabis at scale
- Taking the Dutch cannabis seed production process to the Canadian market
- “$13 million government grant shows trust in the NZ organic medicinal cannabis industry”
Aurora launches new EU GMP extracts to expand options for UK patients
Publication date:
Receive the daily newsletter in your email for free | Click here
Other news in this sector:
- 2022-05-17 Drivers: the unsung heroes of the horticultural industry
- 2022-05-17 US (CT): Acreage Holdings launches social equity partnership
- 2022-05-17 US: Launch of first concentrates in New Jersey
- 2022-05-17 US: Collaboration to support New Jersey cannabis businesses in finding employees
- 2022-05-17 Franchise Global Health to acquire German distributor of medical cannabis
- 2022-05-16 “I knew we needed Dutch expertise to start successful cannabis production in Thailand”
- 2022-05-16 Danish grower delivers first product batch to the new market
- 2022-05-16 "This partnership will result in introduction of forward-thinking cultivars"
- 2022-05-16 NZ: "Medicinal cannabis has the potential to become one of NZ's largest export earners"
- 2022-05-16 Geysir glass: getting growers back in business with energy-saving single glass
- 2022-05-16 Spraying robot converted into a disinfection machine after mounting an extra reel
- 2022-05-13 TerrAscend appoints Lynn Gefen as Chief Legal Officer
- 2022-05-13 US (RI): Medical cannabis grower gets dispensary license
- 2022-05-13 US (VT): Bringing robust safety compliance testing to Vermont's patients and consumers
- 2022-05-13 Aurora to shut down Aurora Sky facility
- 2022-05-13 US (PA): Cannabis grower purchases $10 million facility, $15 million expansion underway
- 2022-05-13 “Our goal is to put together a North American platform to better serve growers”
- 2022-05-12 "We now have the ability to pull an additional 60 new cultivars per year"
- 2022-05-12 Greenway Greenhouse provides medical access to cannabis through North 40
- 2022-05-12 US (MA): Interim Chairman announced for the Cannabis Control Commission